Advanced Search
Display options
Filter resources
Text Availability
Article type
Publication date
Species
Language
Sex
Age
Showing 1 to 12 of 60 entries
Sorted by: Best Match Show Resources per page
Resistive index as a predictor of renal progression in patients with moderate renal dysfunction regardless of angiotensin converting enzyme inhibitor or angiotensin receptor antagonist medication.

Kidney research and clinical practice

Kim JH, Lee SM, Son YK, Kim SE, An WS.
PMID: 28392998
Kidney Res Clin Pract. 2017 Mar;36(1):58-67. doi: 10.23876/j.krcp.2017.36.1.58. Epub 2017 Mar 31.

BACKGROUND: Previous studies have shown that a higher resistive index (RI) on renal duplex ultrasonography was related with renal progression and acute kidney injury, especially in patients with chronic kidney disease (CKD) using an angiotensin converting enzyme inhibitor (ACEI)...

Cite
Kim JH, Lee SM, Son YK, et al. Resistive index as a predictor of renal progression in patients with moderate renal dysfunction regardless of angiotensin converting enzyme inhibitor or angiotensin receptor antagonist medication. Kidney Res Clin Pract. 2017;36(1):58-67doi: 10.23876/j.krcp.2017.36.1.58.
Kim, J. H., Lee, S. M., Son, Y. K., Kim, S. E., & An, W. S. (2017). Resistive index as a predictor of renal progression in patients with moderate renal dysfunction regardless of angiotensin converting enzyme inhibitor or angiotensin receptor antagonist medication. Kidney research and clinical practice, 36(1), 58-67. https://doi.org/10.23876/j.krcp.2017.36.1.58
Kim, Jae Hoon, et al. "Resistive index as a predictor of renal progression in patients with moderate renal dysfunction regardless of angiotensin converting enzyme inhibitor or angiotensin receptor antagonist medication." Kidney research and clinical practice vol. 36,1 (2017): 58-67. doi: https://doi.org/10.23876/j.krcp.2017.36.1.58
Kim JH, Lee SM, Son YK, Kim SE, An WS. Resistive index as a predictor of renal progression in patients with moderate renal dysfunction regardless of angiotensin converting enzyme inhibitor or angiotensin receptor antagonist medication. Kidney Res Clin Pract. 2017 Mar;36(1):58-67. doi: 10.23876/j.krcp.2017.36.1.58. Epub 2017 Mar 31. PMID: 28392998; PMCID: PMC5331976.
Copy Download .nbib Format: NLM
Secondary and Infiltrative Cardiomyopathies.

Current treatment options in cardiovascular medicine

Saltzberg MT.
PMID: 11096542
Curr Treat Options Cardiovasc Med. 2000 Oct;2(5):373-384. doi: 10.1007/s11936-000-0033-y.

Secondary and infiltrative cardiomyopathies are the least common forms of cardiomyopathy and often are the most difficult to treat. In all cases, efforts should be made to establish a specific diagnosis because the removal or avoidance of the causative...

Cite
Saltzberg MT. Secondary and Infiltrative Cardiomyopathies. Curr Treat Options Cardiovasc Med. 2000;2(5):373-384doi: 10.1007/s11936-000-0033-y.
Saltzberg, M. T. (2000). Secondary and Infiltrative Cardiomyopathies. Current treatment options in cardiovascular medicine, 2(5), 373-384. https://doi.org/10.1007/s11936-000-0033-y
Saltzberg. "Secondary and Infiltrative Cardiomyopathies." Current treatment options in cardiovascular medicine vol. 2,5 (2000): 373-384. doi: https://doi.org/10.1007/s11936-000-0033-y
Saltzberg MT. Secondary and Infiltrative Cardiomyopathies. Curr Treat Options Cardiovasc Med. 2000 Oct;2(5):373-384. doi: 10.1007/s11936-000-0033-y. PMID: 11096542.
Copy Download .nbib Format: NLM
Angiotensin receptor antagonists to prevent sudden death in heart failure: does the dose matter?.

ISRN cardiology

Francia P, Palano F, Tocci G, Adduci C, Ricotta A, Semprini L, Caprinozzi M, Balla C, Volpe M.
PMID: 24653841
ISRN Cardiol. 2014 Feb 06;2014:652421. doi: 10.1155/2014/652421. eCollection 2014.

International guidelines recommend ICD implantation in patients with severe left ventricular dysfunction of any origin only after careful optimization of medical therapy. Indeed, major randomized clinical trials suggest that suboptimal use of fundamental drugs, such as ACE inhibitors (ACE-i)...

Cite
Francia P, Palano F, Tocci G, et al. Angiotensin receptor antagonists to prevent sudden death in heart failure: does the dose matter?. ISRN Cardiol. 2014;2014:652421doi: 10.1155/2014/652421.
Francia, P., Palano, F., Tocci, G., Adduci, C., Ricotta, A., Semprini, L., Caprinozzi, M., Balla, C., & Volpe, M. (2014). Angiotensin receptor antagonists to prevent sudden death in heart failure: does the dose matter?. ISRN cardiology, 2014652421. https://doi.org/10.1155/2014/652421
Francia, Pietro, et al. "Angiotensin receptor antagonists to prevent sudden death in heart failure: does the dose matter?." ISRN cardiology vol. 2014 (2014): 652421. doi: https://doi.org/10.1155/2014/652421
Francia P, Palano F, Tocci G, Adduci C, Ricotta A, Semprini L, Caprinozzi M, Balla C, Volpe M. Angiotensin receptor antagonists to prevent sudden death in heart failure: does the dose matter?. ISRN Cardiol. 2014 Feb 06;2014:652421. doi: 10.1155/2014/652421. eCollection 2014. PMID: 24653841; PMCID: PMC3933036.
Copy Download .nbib Format: NLM
Upstream Therapy for Atrial Fibrillation Prevention: The Role of Sacubitril/Valsartan.

Cardiology research

De Vecchis R, Paccone A, Di Maio M.
PMID: 32595805
Cardiol Res. 2020 Aug;11(4):213-218. doi: 10.14740/cr1073. Epub 2020 Jun 03.

The therapy or prevention of atrial fibrillation (AF) is defined as upstream therapy when conducted with the use of drugs, e.g., angiotensin-converting enzyme inhibitors (ACEIs), angiotensin receptor antagonists, statins, and omega-3 fatty acids, not included in the classes of...

Cite
De Vecchis R, Paccone A, Di Maio M. Upstream Therapy for Atrial Fibrillation Prevention: The Role of Sacubitril/Valsartan. Cardiol Res. 2020;11(4):213-218doi: 10.14740/cr1073.
De Vecchis, R., Paccone, A., & Di Maio, M. (2020). Upstream Therapy for Atrial Fibrillation Prevention: The Role of Sacubitril/Valsartan. Cardiology research, 11(4), 213-218. https://doi.org/10.14740/cr1073
De Vecchis, Renato, et al. "Upstream Therapy for Atrial Fibrillation Prevention: The Role of Sacubitril/Valsartan." Cardiology research vol. 11,4 (2020): 213-218. doi: https://doi.org/10.14740/cr1073
De Vecchis R, Paccone A, Di Maio M. Upstream Therapy for Atrial Fibrillation Prevention: The Role of Sacubitril/Valsartan. Cardiol Res. 2020 Aug;11(4):213-218. doi: 10.14740/cr1073. Epub 2020 Jun 03. PMID: 32595805; PMCID: PMC7295563.
Copy Download .nbib Format: NLM
Glucagonoma-associated dilated cardiomyopathy refractory to somatostatin analogue therapy.

Endocrinology, diabetes & metabolism case reports

Barabas M, Huang-Doran I, Pitfield D, Philips H, Goonewardene M, Casey RT, Challis BG.
PMID: 30836327
Endocrinol Diabetes Metab Case Rep. 2019 Mar 05;2019. doi: 10.1530/EDM-18-0157. Epub 2019 Mar 05.

A 67-year-old woman presented with a generalised rash associated with weight loss and resting tachycardia. She had a recent diagnosis of diabetes mellitus. Biochemical evaluation revealed elevated levels of circulating glucagon and chromogranin B. Cross-sectional imaging demonstrated a pancreatic...

Cite
Barabas M, Huang-Doran I, Pitfield D, et al. Glucagonoma-associated dilated cardiomyopathy refractory to somatostatin analogue therapy. Endocrinol Diabetes Metab Case Rep. 2019;2019doi: 10.1530/EDM-18-0157.
Barabas, M., Huang-Doran, I., Pitfield, D., Philips, H., Goonewardene, M., Casey, R. T., & Challis, B. G. (2019). Glucagonoma-associated dilated cardiomyopathy refractory to somatostatin analogue therapy. Endocrinology, diabetes & metabolism case reports, 2019. https://doi.org/10.1530/EDM-18-0157
Barabas, Michal, et al. "Glucagonoma-associated dilated cardiomyopathy refractory to somatostatin analogue therapy." Endocrinology, diabetes & metabolism case reports vol. 2019 (2019). doi: https://doi.org/10.1530/EDM-18-0157
Barabas M, Huang-Doran I, Pitfield D, Philips H, Goonewardene M, Casey RT, Challis BG. Glucagonoma-associated dilated cardiomyopathy refractory to somatostatin analogue therapy. Endocrinol Diabetes Metab Case Rep. 2019 Mar 05;2019. doi: 10.1530/EDM-18-0157. Epub 2019 Mar 05. PMID: 30836327; PMCID: PMC6432982.
Copy Download .nbib Format: NLM
Association between COVID-19 and cardiovascular disease.

International journal of cardiology. Heart & vasculature

Srivastava K.
PMID: 32715080
Int J Cardiol Heart Vasc. 2020 Jul 14;29:100583. doi: 10.1016/j.ijcha.2020.100583. eCollection 2020 Aug.

Severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2), which causes coronavirus disease 2019 (COVID-19) has reached a pandemic level. SARS-CoV-2 infects host cells through ACE2 receptors, leading to COVID-19-related pneumonia. The rapid increase in confirmed cases makes the prevention and...

Cite
Srivastava K. Association between COVID-19 and cardiovascular disease. Int J Cardiol Heart Vasc. 2020;29:100583doi: 10.1016/j.ijcha.2020.100583.
Srivastava, K. (2020). Association between COVID-19 and cardiovascular disease. International journal of cardiology. Heart & vasculature, 29100583. https://doi.org/10.1016/j.ijcha.2020.100583
Srivastava, Kamna. "Association between COVID-19 and cardiovascular disease." International journal of cardiology. Heart & vasculature vol. 29 (2020): 100583. doi: https://doi.org/10.1016/j.ijcha.2020.100583
Srivastava K. Association between COVID-19 and cardiovascular disease. Int J Cardiol Heart Vasc. 2020 Jul 14;29:100583. doi: 10.1016/j.ijcha.2020.100583. eCollection 2020 Aug. PMID: 32715080; PMCID: PMC7359796.
Copy Download .nbib Format: NLM
Impact of Angiotensin-Converting Enzyme Inhibitors and Angiotensin Receptor Blockers on Renal Function in Type 1 Cardiorenal Syndrome.

Journal of cardiovascular pharmacology and therapeutics

Ilges DT, Dermody ML, Blankenship C, Mansfield V, Van Tuyl JS.
PMID: 34138673
J Cardiovasc Pharmacol Ther. 2021 Nov;26(6):611-618. doi: 10.1177/10742484211022625. Epub 2021 Jun 17.

INTRODUCTION: Angiotensin-converting enzyme inhibitor (ACE-I) and angiotensin receptor blocker (ARB) discontinuation during acute heart failure (AHF) is associated with increased mortality following hospitalization. Although the etiology of acute kidney injury (AKI) in type 1 cardiorenal syndrome (CRS) has been...

Cite
Ilges DT, Dermody ML, Blankenship C, et al. Impact of Angiotensin-Converting Enzyme Inhibitors and Angiotensin Receptor Blockers on Renal Function in Type 1 Cardiorenal Syndrome. J Cardiovasc Pharmacol Ther. 2021;26(6):611-618doi: 10.1177/10742484211022625.
Ilges, D. T., Dermody, M. L., Blankenship, C., Mansfield, V., & Van Tuyl, J. S. (2021). Impact of Angiotensin-Converting Enzyme Inhibitors and Angiotensin Receptor Blockers on Renal Function in Type 1 Cardiorenal Syndrome. Journal of cardiovascular pharmacology and therapeutics, 26(6), 611-618. https://doi.org/10.1177/10742484211022625
Ilges, Daniel T, et al. "Impact of Angiotensin-Converting Enzyme Inhibitors and Angiotensin Receptor Blockers on Renal Function in Type 1 Cardiorenal Syndrome." Journal of cardiovascular pharmacology and therapeutics vol. 26,6 (2021): 611-618. doi: https://doi.org/10.1177/10742484211022625
Ilges DT, Dermody ML, Blankenship C, Mansfield V, Van Tuyl JS. Impact of Angiotensin-Converting Enzyme Inhibitors and Angiotensin Receptor Blockers on Renal Function in Type 1 Cardiorenal Syndrome. J Cardiovasc Pharmacol Ther. 2021 Nov;26(6):611-618. doi: 10.1177/10742484211022625. Epub 2021 Jun 17. PMID: 34138673.
Copy Download .nbib Format: NLM
Impact of Angiotensin-Converting Enzyme Inhibitors and Angiotensin Receptor Blockers on Renal Function in Type 1 Cardiorenal Syndrome.

Journal of cardiovascular pharmacology and therapeutics

Ilges DT, Dermody ML, Blankenship C, Mansfield V, Van Tuyl JS.
PMID: 34138673
J Cardiovasc Pharmacol Ther. 2021 Nov;26(6):611-618. doi: 10.1177/10742484211022625. Epub 2021 Jun 17.

INTRODUCTION: Angiotensin-converting enzyme inhibitor (ACE-I) and angiotensin receptor blocker (ARB) discontinuation during acute heart failure (AHF) is associated with increased mortality following hospitalization. Although the etiology of acute kidney injury (AKI) in type 1 cardiorenal syndrome (CRS) has been...

Cite
Ilges DT, Dermody ML, Blankenship C, et al. Impact of Angiotensin-Converting Enzyme Inhibitors and Angiotensin Receptor Blockers on Renal Function in Type 1 Cardiorenal Syndrome. J Cardiovasc Pharmacol Ther. 2021;26(6):611-618doi: 10.1177/10742484211022625.
Ilges, D. T., Dermody, M. L., Blankenship, C., Mansfield, V., & Van Tuyl, J. S. (2021). Impact of Angiotensin-Converting Enzyme Inhibitors and Angiotensin Receptor Blockers on Renal Function in Type 1 Cardiorenal Syndrome. Journal of cardiovascular pharmacology and therapeutics, 26(6), 611-618. https://doi.org/10.1177/10742484211022625
Ilges, Daniel T, et al. "Impact of Angiotensin-Converting Enzyme Inhibitors and Angiotensin Receptor Blockers on Renal Function in Type 1 Cardiorenal Syndrome." Journal of cardiovascular pharmacology and therapeutics vol. 26,6 (2021): 611-618. doi: https://doi.org/10.1177/10742484211022625
Ilges DT, Dermody ML, Blankenship C, Mansfield V, Van Tuyl JS. Impact of Angiotensin-Converting Enzyme Inhibitors and Angiotensin Receptor Blockers on Renal Function in Type 1 Cardiorenal Syndrome. J Cardiovasc Pharmacol Ther. 2021 Nov;26(6):611-618. doi: 10.1177/10742484211022625. Epub 2021 Jun 17. PMID: 34138673.
Copy Download .nbib Format: NLM
Angiotensin-converting enzyme inhibitors versus angiotensin receptor blockers: New-onset diabetes mellitus stratified by statin use.

Journal of clinical pharmacy and therapeutics

Shin J, Kim H, Yim HW, Kim JH, Lee S, Kim HS.
PMID: 34668200
J Clin Pharm Ther. 2021 Oct 20; doi: 10.1111/jcpt.13544. Epub 2021 Oct 20.

WHAT IS KNOWN AND OBJECTIVES: Regardless of statin use, which is known to induce hyperglycaemia, comparative studies on the risk of new-onset diabetes mellitus (NODM) with angiotensin-converting enzyme inhibitors (ACEIs) and angiotensin II receptor blockers (ARBs) are needed. This...

Cite
Shin J, Kim H, Yim HW, et al. Angiotensin-converting enzyme inhibitors versus angiotensin receptor blockers: New-onset diabetes mellitus stratified by statin use. J Clin Pharm Ther. 2021;doi: 10.1111/jcpt.13544.
Shin, J., Kim, H., Yim, H. W., Kim, J. H., Lee, S., & Kim, H. S. (2021). Angiotensin-converting enzyme inhibitors versus angiotensin receptor blockers: New-onset diabetes mellitus stratified by statin use. Journal of clinical pharmacy and therapeutics, . https://doi.org/10.1111/jcpt.13544
Shin, Juyoung, et al. "Angiotensin-converting enzyme inhibitors versus angiotensin receptor blockers: New-onset diabetes mellitus stratified by statin use." Journal of clinical pharmacy and therapeutics vol. (2021). doi: https://doi.org/10.1111/jcpt.13544
Shin J, Kim H, Yim HW, Kim JH, Lee S, Kim HS. Angiotensin-converting enzyme inhibitors versus angiotensin receptor blockers: New-onset diabetes mellitus stratified by statin use. J Clin Pharm Ther. 2021 Oct 20; doi: 10.1111/jcpt.13544. Epub 2021 Oct 20. PMID: 34668200.
Copy Download .nbib Format: NLM
Efficacy and safety of angiotensin-converting enzyme inhibitors or angiotensin receptor blockers for IgA nephropathy in children.

Pediatric nephrology (Berlin, Germany)

Vaz de Castro PAS, Bitencourt L, Pereira BWS, Lima AQR, Hermida HS, Moreira Neto CR, Mestriner MD, Simões E Silva AC.
PMID: 34686915
Pediatr Nephrol. 2021 Oct 22; doi: 10.1007/s00467-021-05316-0. Epub 2021 Oct 22.

BACKGROUND: IgA nephropathy (IgAN) is one of the most prevalent primary glomerulopathies in children. There are various studies investigating the efficacy of angiotensin-converting enzyme inhibitors (ACEI) and angiotensin II receptor blockers (ARB) in adults with IgAN. However, only few...

Cite
Vaz de Castro PAS, Bitencourt L, Pereira BWS, et al. Efficacy and safety of angiotensin-converting enzyme inhibitors or angiotensin receptor blockers for IgA nephropathy in children. Pediatr Nephrol. 2021;doi: 10.1007/s00467-021-05316-0.
Vaz de Castro, P. A. S., Bitencourt, L., Pereira, B. W. S., Lima, A. Q. R., Hermida, H. S., Moreira Neto, C. R., Mestriner, M. D., & Simões E Silva, A. C. (2021). Efficacy and safety of angiotensin-converting enzyme inhibitors or angiotensin receptor blockers for IgA nephropathy in children. Pediatric nephrology (Berlin, Germany), . https://doi.org/10.1007/s00467-021-05316-0
Vaz de Castro, Pedro Alves Soares, et al. "Efficacy and safety of angiotensin-converting enzyme inhibitors or angiotensin receptor blockers for IgA nephropathy in children." Pediatric nephrology (Berlin, Germany) vol. (2021). doi: https://doi.org/10.1007/s00467-021-05316-0
Vaz de Castro PAS, Bitencourt L, Pereira BWS, Lima AQR, Hermida HS, Moreira Neto CR, Mestriner MD, Simões E Silva AC. Efficacy and safety of angiotensin-converting enzyme inhibitors or angiotensin receptor blockers for IgA nephropathy in children. Pediatr Nephrol. 2021 Oct 22; doi: 10.1007/s00467-021-05316-0. Epub 2021 Oct 22. PMID: 34686915.
Copy Download .nbib Format: NLM
Comparative Efficacy and Safety of BP-Lowering Pharmacotherapy in Patients Undergoing Maintenance Dialysis: A Network Meta-Analysis of Randomized, Controlled Trials.

Clinical journal of the American Society of Nephrology : CJASN

Shaman AM, Smyth B, Arnott C, Palmer SC, Mihailidou AS, Jardine MJ, Gallagher MP, Perkovic V, Jun M.
PMID: 32675281
Clin J Am Soc Nephrol. 2020 Aug 07;15(8):1129-1138. doi: 10.2215/CJN.12201019. Epub 2020 Jul 16.

BACKGROUND AND OBJECTIVES: Elevated BP is an important risk factor for cardiovascular disease, with a prevalence of over 80% in patients undergoing maintenance dialysis. We assessed the comparative BP-lowering efficacy and the safety of BP-lowering drugs in patients undergoing...

Cite
Shaman AM, Smyth B, Arnott C, et al. Comparative Efficacy and Safety of BP-Lowering Pharmacotherapy in Patients Undergoing Maintenance Dialysis: A Network Meta-Analysis of Randomized, Controlled Trials. Clin J Am Soc Nephrol. 2020;15(8):1129-1138doi: 10.2215/CJN.12201019.
Shaman, A. M., Smyth, B., Arnott, C., Palmer, S. C., Mihailidou, A. S., Jardine, M. J., Gallagher, M. P., Perkovic, V., & Jun, M. (2020). Comparative Efficacy and Safety of BP-Lowering Pharmacotherapy in Patients Undergoing Maintenance Dialysis: A Network Meta-Analysis of Randomized, Controlled Trials. Clinical journal of the American Society of Nephrology : CJASN, 15(8), 1129-1138. https://doi.org/10.2215/CJN.12201019
Shaman, Ahmed M, et al. "Comparative Efficacy and Safety of BP-Lowering Pharmacotherapy in Patients Undergoing Maintenance Dialysis: A Network Meta-Analysis of Randomized, Controlled Trials." Clinical journal of the American Society of Nephrology : CJASN vol. 15,8 (2020): 1129-1138. doi: https://doi.org/10.2215/CJN.12201019
Shaman AM, Smyth B, Arnott C, Palmer SC, Mihailidou AS, Jardine MJ, Gallagher MP, Perkovic V, Jun M. Comparative Efficacy and Safety of BP-Lowering Pharmacotherapy in Patients Undergoing Maintenance Dialysis: A Network Meta-Analysis of Randomized, Controlled Trials. Clin J Am Soc Nephrol. 2020 Aug 07;15(8):1129-1138. doi: 10.2215/CJN.12201019. Epub 2020 Jul 16. PMID: 32675281; PMCID: PMC7409758.
Copy Download .nbib Format: NLM
Pneumoperitoneum in laparoscopy and preoperative antihypertensive agents: A retrospective study.

Experimental and therapeutic medicine

Kim H.
PMID: 31777554
Exp Ther Med. 2019 Dec;18(6):4517-4522. doi: 10.3892/etm.2019.8076. Epub 2019 Oct 03.

The purpose of the current study was to investigate the effects of preoperative antihypertensive agents on blood pressure (BP) changes after intraperitoneal CO

Cite
Kim H. Pneumoperitoneum in laparoscopy and preoperative antihypertensive agents: A retrospective study. Exp Ther Med. 2019;18(6):4517-4522doi: 10.3892/etm.2019.8076.
Kim, H. (2019). Pneumoperitoneum in laparoscopy and preoperative antihypertensive agents: A retrospective study. Experimental and therapeutic medicine, 18(6), 4517-4522. https://doi.org/10.3892/etm.2019.8076
Kim, Hyunjee. "Pneumoperitoneum in laparoscopy and preoperative antihypertensive agents: A retrospective study." Experimental and therapeutic medicine vol. 18,6 (2019): 4517-4522. doi: https://doi.org/10.3892/etm.2019.8076
Kim H. Pneumoperitoneum in laparoscopy and preoperative antihypertensive agents: A retrospective study. Exp Ther Med. 2019 Dec;18(6):4517-4522. doi: 10.3892/etm.2019.8076. Epub 2019 Oct 03. PMID: 31777554; PMCID: PMC6862321.
Copy Download .nbib Format: NLM
Showing 1 to 12 of 60 entries